Clinical Trial Update: Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial results for CPX-351 in adults with first-relapse Acute Myeloid Leukemia have been completed, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CPX-351 (liposomal daunorubicin/cytarabine)

Snippet

Sponsor: Jazz Pharmaceuticals | Conditions: Acute Myeloid Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2017-09-29